$MNTA News
Last published 6y ago
- 6y agoMNTAMomenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & JohnsonGlobeNewswireCAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel...
- 6y agoMNTAMomenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & JohnsonGlobeNewswireCAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel...
- 6y agoMNTANew patent granted for: Methods of Manufacturing Therapeutic ProteinsUS Patent Applications (USPTO)
- 6y agoMNTAONDKAIMTOTELMoore Kuehn Encourages MNTA, AIMT, ONDK, and OTEL Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoNTNPRNBMNTAPFNXMoore Kuehn Encourages NTN, PRNB, MNTA, and PFNX Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 6y agoCNSPMNTAABBVBMY+2Clinical Trials Testing New Paradigms For Advanced Therapies Treating Metastatic Cancer ConditionsPR NewswireVarious reports on the global metastatic cancer treatment market all project continued growth in the next several years. One such report from...
- 6y agoTGTAAPLCREETJX+6Stocks making the biggest moves midday: Target, Apple, Momenta, BioMarin & moreCNBCCheck out the companies making headlines in midday trading.
- 6y agoTGTLOWWMTHD+45 things to know before the stock market opens WednesdayCNBCThe S&P 500 was pacing to add to Tuesday's record close as Target and Lowe's reported blowout earnings.
- 6y agoTGTLOWMNTAJNJ+12Stocks making the biggest moves in the premarket: Target, Lowe's, J&J, Momenta, Gilead & moreCNBCThe stocks making the biggest moves in premarket trading include Target, Lowe's, J&J, Momenta, Gilead, and more.
- 6y agoPRNBMNTAJNJJ&J to Buy Momenta for About $6.5 Billion for Autoimmune DrugsBloombergJohnson & Johnson agreed to buy Momenta Pharmaceuticals Inc. for about $6.5 billion to expand in treatments for autoimmune diseases.
- 6y agoJNJMNTAJohnson & Johnson to buy Momenta for about $6.5 billionCNBCJohnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals for about $6.5 billion in cash to expand into the area of autoimmune disease treatments.
- 6y agoMNTAMomenta Enters Definitive Agreement with Johnson & JohnsonGlobeNewswireJohnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020 ...
- 6y agoMNTANew patent application published for: Methods for Predicting Response to TreatmentUS Patent Applications (USPTO)
- 6y agoMNTAMomenta Pharmaceuticals Reports Second Quarter 2020 Financial and Operating ResultsGlobeNewswire-- Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p<0.0001) between...
- 6y agoMNTAMomenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and WebcastGlobeNewswireCAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
- 6y agoMNTAMomenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFNGlobeNewswireCAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease...
- 6y agoMNTAMomenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)GlobeNewswire- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001) - - Nipocalimab induced a rapid and durable response...
- 6y agoMNTAMomenta Provides Corporate Update Amid COVID-19 PandemicGlobeNewswireCAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
- 6y agoMNTANew patent application published for: Sialylated GlycoproteinsUS Patent Applications (USPTO)( 1 of 1 )
- 6y agoMNTAMomenta Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial ResultsGlobeNewswire-- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020...
- 6y agoMNTAMomenta Provides Year-End 2019 Update and 2020 OutlookGlobeNewswire-- Interim Phase 1 / 2 data of M254 in ITP supports expansion of lower dose cohorts; additional data expected Q2; plan to initiate Phase 2 study in CIDP – -- Nipocalimab (M281) MG study 80% enrolled;...
- 6y agoMNTAMomenta Pharmaceuticals Announces CFO TransitionGlobeNewswireCAMBRIDGE, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) (“Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel...
- 6y agoMNTAMomenta Pharmaceuticals to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Dec. 24, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that Craig Wheeler, President and CEO, will present at the 38th Annual J.P. Morgan...
- 6y agoMNTAMomenta Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of...
- 7y agoMNTAMomenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and ExpositionGlobeNewswireCAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster...
- 7y agoMNTAMomenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating ResultsGlobeNewswireCAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
- 7y agoMNTAMomenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoMNTAMomenta Pharmaceuticals Inc's (MNTA) CEO Craig Wheeler on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 9y agoMNTAMomenta Pharmaceuticals (MNTA) CEO on Craig Wheeler on 2017 Wells Fargo Healthcare Conference TranscriptEarnings Call Transcripts
- 10y agoMNTAMomenta Pharmaceuticals' (MNTA) Management Presents at Wells Fargo Securities Health Care ConferenceEarnings Call Transcripts
- 10y agoMNTAMomenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts
- 11y agoBXLTMNTACTICBaxalta Announces Strong Sales and Earnings for Third Quarter Exceeding Guidance, Raises Second Half 2015 OutlookBusiness WireBANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT) today reported strong third quarter financial results, exceeding its previously-issued sales and earnings guidance. The company also raised its outlook for the second half of 2015 and provided preliminary 2016 guidance.
- 14y agoBAXMNTABaxter and Momenta Announce Collaboration to Develop and Commercialize Follow-On BiologicsBusiness WireDEERFIELD, Ill. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that they have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars. Biosimilars replicate existing, branded biologics used in the treatment of a variety of diseases including can ...